ArticleJournal of clinical biochemistry and nutrition2018
Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study.
Article in Journal of clinical biochemistry and nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment ofAnnals of medicine · 2026Trial
- Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.European journal of clinical pharmacology · 2022Trial
- Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.British journal of clinical pharmacology · 2022Trial
- Association between Gastric Acid Suppression Therapy and Scattered White Spots in the Duodenum: A Retrospective Observational Study.Endoscopy international open · 2026Article
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease.Drugs · 2025Review
- Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.Alimentary pharmacology & therapeutics · 2025Article
- Comparison of the preventive effects of proton pump inhibitors and vonoprazan on delayed bleeding after gastric endoscopic submucosal dissection.Therapeutic advances in gastroenterology · 2025Article
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.Current gastroenterology reports · 2024Review
- Review
- Diagnostic and therapeutic recommendations onPrzeglad gastroenterologiczny · 2023Article
- Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study.Journal of clinical biochemistry and nutrition · 2021Article
- Influence of acotiamide onJournal of clinical biochemistry and nutrition · 2020Article
- Update on the Management ofCurrent treatment options in gastroenterology · 2020Review
- Potent Acid Suppression with PPIs and P-CABs: What's New?Current treatment options in gastroenterology · 2018Review
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To promote symptom relief from acid-related diseases, a medicine with a rapid-onset effect is ideal. The aim of this study was to investigate the early inhibitory effect on gastric acid secretion after a single oral administration of vonoprazan, which represents a new class of proton pump inhibitors, and to compare this effect with those of lansoprazole and famotidine. Ten
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.